Exelixis, Inc. (EXEL)
- Previous Close
23.29 - Open
23.20 - Bid 23.67 x 300
- Ask 23.72 x 900
- Day's Range
23.19 - 23.78 - 52 Week Range
18.08 - 24.34 - Volume
1,466,092 - Avg. Volume
2,237,183 - Market Cap (intraday)
6.99B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
36.48 - EPS (TTM)
0.65 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.74
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
www.exelixis.comRecent News: EXEL
Performance Overview: EXEL
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EXEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EXEL
Valuation Measures
Market Cap
6.99B
Enterprise Value
6.18B
Trailing P/E
36.48
Forward P/E
18.38
PEG Ratio (5yr expected)
1.75
Price/Sales (ttm)
4.16
Price/Book (mrq)
3.09
Enterprise Value/Revenue
3.38
Enterprise Value/EBITDA
31.46
Financial Highlights
Profitability and Income Statement
Profit Margin
11.35%
Return on Assets (ttm)
3.55%
Return on Equity (ttm)
8.74%
Revenue (ttm)
1.83B
Net Income Avi to Common (ttm)
207.76M
Diluted EPS (ttm)
0.65
Balance Sheet and Cash Flow
Total Cash (mrq)
995.3M
Total Debt/Equity (mrq)
9.53%
Levered Free Cash Flow (ttm)
125.4M
Research Analysis: EXEL
Company Insights: EXEL
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: EXEL
EXEL: What does Argus have to say about EXEL?
EXELIXIS INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetEXEL: Lowering target price to $24.00
EXELIXIS INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetEXEL: What does Argus have to say about EXEL?
EXELIXIS INC has an Investment Rating of HOLD; a target price of $25.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetAnalyst Report: Exelixis, Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
RatingPrice Target